The role of fluoroquinolones in the treatment of patients hospitalised with community-acquired pneumonia

Francesco Blasi, Federico Piffer, Maddalena Zanardelli, Paolo Tarsia

Research output: Contribution to journalArticle

Abstract

Despite advances in antimicrobial therapy, community-acquired pneumonia (CAP) remains a common and potentially life-threatening infection. Fluoroquinolones appear to be a valid monotherapy alternative to the combination beta-lactam/macrolide therapy for non-severe hospitalised CAP, particularly in regions with a high prevalence of penicillin-resistant Streptococcus pneumoniae (PRSP) or in patients with a clinical risk of PRSP, and a key partner in the combination therapy given in casesof severe and intensive care unit-admitted CAP and when Pseudomonas aeruginosa infection is suspected. The high bioavailability of fluoroquinolones facilitates an early switch from intravenous to oral therapy.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalEuropean Respiratory Disease
Volume8
Issue number1
Publication statusPublished - Mar 2012

Keywords

  • Antibiotic resistance
  • Community-acquired pneumonia
  • Fluoroquinolones

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'The role of fluoroquinolones in the treatment of patients hospitalised with community-acquired pneumonia'. Together they form a unique fingerprint.

  • Cite this